(Mead Johnson & Co.) A dangerous drug which can cause death. This FDA-approved “anticancer” drug actually can also cause cancer, namely secondary malignancies. According to the FDA-approved “safety” data: “the possibility of secondary malignancy, based on available data, should be considered in any benefit-to-risk assessment for the use of the drug.” In addition to causing cancer and death, numerous side-effects can occur from this drug, including destruction of immune systems, leucopenia, hemorrhage, gonadal suppression, resulting in amenorrhea or azoospermia, possibly “irreversible”. The drug is not represented to be cancer-curative.
(Adria laboratories, Inc.) The FDA-approved data on “safety” states that special attention “must be given to the cardiac toxicity” exhibited by this drug. Such labeling data further states that “Congestive heart failure and/or cardiomyopathy may be encountered several weeks after discontinuation” of therapy with this drug, and that cardiac failure is often “not favorably affected by presently known medical or physical therapy for cardiac support.” According to such labeling, there is a “high incidence of bone marrow depression” and administration of the drug “may result in superinfection or hemorrhage.” Numerous severe and body-damaging adverse reactions are also listed in the approved labeling, including acute nausea and vomiting, phlebosclerosis, severe cellulitis, vesication and tissue necrosis (death), fever, chills and anaphylaxis. The drug is not stated to be cancer curative.
(Adria Laboratories, Inc.) According to the manufacturer’s FDA-approved “safety” data, this is a “highly toxic drug with a narrow margin of safety.” It is further stated that “severe hematologic toxicity, gastrointestinal hemorrhage, and even death may result” from use of this drug, despite “meticulous selection of patients and careful adjustment of dosage.” “Myelosuppression” (bone marrow suppression, particularly spinal) “almost uniformly accompanies a course of adequate therapy” with this drug, according to the aforesaid FDA approved labeling. Other and severe dangerous effects are also described in such labeling. The alleged benefits are stated to be “palliative” (i.e., “affecting relief, not cure”).
(Bristol Laboratories, Division of Bristol Myers Co.) According to the FDA-approved “safety” data for this drug, “delayed bone marrow toxicity” is the major toxicity. Other and serious side effects and adverse reactions are also listed. Additionally, the drug causes cancer, the FDA approved labeling stating “BICNU is carinogenic in rats and mice, producing a marked increase in tumor incidence in doses approximating those employed clinically.” Alleged “benefits” are stated to be “palliative.”
(Bristol Laboratories, Division of Bristol Myers Co.) The FDA-approved “safety information” for this drug lists as the “major toxicity” delayed bone marrow suppression. The official labeling also lists cumulative myelosuppression as an effect which can result from this drug. It is also stated: “Neurological reactions such as disorientation, lethargy, ataxia (failure of muscular co9rdination) and dysarthria” (impaired speech) “have been noted in some patients receiving CeeNu. “Alleged benefits” are stated to be “palliative.”
(Dome Division, Miles Laboratories, Inc.) The “safety” data approved by FDA for this drug states: “Leukopenia and thrombocytopenia may be severe enough to cause death.” According to FDA-approved labeling, more than 90% of patients are affected with the initial few doses as to anorexia, nausea and vomiting, among other things. The drug is not stated to be cancercurative.
(Bristol Laboratories, Division of Bristol Myers Co.) The FDA-approved “safety” data for this product states: “Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of Mutamycin.” “Elsewhere in the FDA-approved labeling, it is stated that such bone marrow toxicity occurred in 64.4% of a group of patients tested. It is also stated that: “About 25% of the leukopenic or thrombocytopenic episodes did not recover” (i.e., died). Among the other “undesirable side effects” listed in the FDA-approved labeling are “headache, blurring of vision, confusion, drowiness, syncope” (i.e., temporary suspension of consciousness), “edema, thrombophlebitis, hematemesis, diarrhea and pain.” In addition, this “anti-cancer” drug causes cancer, with an increase 50% to 100% in cancer tumors, the official FDA-approved labeling stating: “Mutamycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical dose in man, it produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice.” This drug is not alleged to be cancer curative.
(Roche Laboratories) In addition to numerous adverse reactions which are caused by this drug, it is also cancer-causing. According to the FDA approved “safety” data, leukemia, among other things, has resulted from “Mutalane therapy.” Animal tests reveal other forms of cancer caused by administration of the drug, according to the approved labeling.
(Manufactured by Pfizer Laboratories for the Dome Division, Miles Laboratories, Inc.) The FDA-approved “safety” data for this product states: “Severe thrombocytopenia, a hemorrhagic tendency and even death may result from the use of Mithracin.” It is further stated that a detailed analysis of the clinical data in 1,160 patients treated with the drug “indicates that the hemorrhagic syndrome is dose related.” The manufacturer also noted, with FDA approval, that with recommended “doses of 30 meg/kg/day or less for 10 or fewer doses there is an “associated drug-related mortality rate of 1.6%” (16 patients per 1,000 receiving the drug are killed by the drug, in other words, not their cancer). The FDA-approved death rate from this drug rises to 5.7Wo (or 57 per 1,000) however, with a higher dosage of “Mithracin” noted in said approved labeling. The approved labeling also designates a veritable host of other dangerous side effects. The drug is stated not to be cancer-curative.
(Hoffman LaRoche, Inc.) According to the FDA-approved official labeling in effect as of August 1, 1978: “Severe hemotalogical toxicity, gastro-intestinal hemorrhage and even death may result from the use of FUDR despite meticulous selection of patients and careful adjustment of dosage . . . fatalities may be encountered occasionally even in patients in relatively good condition.” Numerous other adverse effects of this dangerous drug include functional gastrointestinal, mucosal gastrointestinal, hematoloic, dermatologic, miscellaneous clinical reactions, laboratory abnormalities and procedural complications of regional arterial infusion, nausea, vomiting, diarrhea, enteritis, stomatitis, and localized erythema, anemia, leukopenia, and others. Alleged “benefits” are stated to be “palliative”.
(Hoffman LaRoche, Inc.) The official FDA approved “safety” labeling in effect as of August 1, 1978 states: “Severe hematological toxicity gastrointestinal hemorrhage and even death may result from the use of Fluorouracil despite meticulous selection of patients and careful adjustment of dosage.” Numerous other adverse and dangerous reactions and side effects are also listed in such official labeling. Alleged “benefits” are stated to be “palliative” only.
(Lederle Laboratories) The “safety” data contained in the FDA-approved labeling for this product states that “sudden death has been reported from use of Methotrexate.” It is also stated that the drug “may produce marked depression of bone marrow, anemia, leukopenia, thrombocytopenia and bleeding.” It may be “hepatoxic” (liver damaging) and cause “liver atrophy, necrosis” (death), “cirrhosis, fatty changes, and periportal fibrosis,” it is also stated that this drug, approved by FDA for its “safety”, may have an “immuno-suppressive action” (i.e., destroying the immune systems of the body). Listed as “common adverse reactions” are included ulcerative stomatitis, leukopenia, nausea and abdominal distress, malaise, decreased resistance to infection, depigmentation, alopecia, hemorrhage from various sites, vomiting,, diarrhea, gastrointestinal ulceration and bleeding, renal (kidney) failure, infertility, abortion, severe nephropathy (kidney disease), blurred vision, paresis (paralysis) and convulsions, ataxia, dementia, precipitating diabetes, osteoporotic effects-(calcium leached from the bones), abnormal tissue cell changes, and others. The drug is not stated to be cancer-curative.
(Bristol Laboratories, Division of Bristol Myers Co.) The FDA-approved “safety” data for this product states: “Pulmonary fibrosis” (i.e., progressive fibrous degeneration of the lung) “is the most severe toxicity associated with Blenoxane.” It is further stated that in approximately 1% of patients treated with Blenoxane, “the nonspecific pneumonitis induced by Blenoxane progresses to pulmonary fibrosis, and death. Although this is age and dose related, the toxicity is unpredictable.” The same FDA approved mortality data is repeated elsewhere: “Approximately 1∞/o of patients treated have died of pulmonary fibrosis.” Numerous other dangerous and harmful effects of this drug are also listed in the FDA-approved representations. The drug is not stated to be cancer-curative.